Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:27 PM EDT
70.47quote price arrow down-1.33 (-1.85%)
Volume
485,161
52 week range
68.04 - 181.83

...

Loading . . .
  • Open71.00
  • Day High72.92
  • Day Low70.04
  • Prev Close71.80
  • 52 Week High181.83
  • 52 Week High Date12/22/20
  • 52 Week Low68.04
  • 52 Week Low Date04/13/21

Key Stats

  • Market Cap5,596.73M
  • Shares Out79.42M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta1.47
  • YTD % Change-58.53

KEY STATS

  • Open71.00
  • Day High72.92
  • Day Low70.04
  • Prev Close71.80
  • 52 Week High181.83
  • 52 Week High Date12/22/20
  • 52 Week Low68.04
  • 52 Week Low Date04/13/21
  • Market Cap5,596.73M
  • Shares Out79.42M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta1.47
  • YTD % Change-58.53

RATIOS/PROFITABILITY

  • EPS (TTM)-7.07
  • P/E (TTM)-9.97
  • Fwd P/E (NTM)-9.47
  • EBITDA (MRQ)-537.25M
  • ROE (MRQ)-70.15%
  • Revenue (MRQ)540.10M
  • Gross Margin (MRQ)88.26%
  • Net Margin (MRQ)-102.60%
  • Debt To Equity (MRQ)130.29%

EVENTS

  • Earnings Date05/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest From Sarepta Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its...
M. Kathleen Behrens Ph.D.
Chairman
Douglas Ingram Esq., J.D.
President
Ian Estepan
Chief Financial Officer
Alexander Cumbo
Executive Vice President
William Ciambrone
Executive Vice President
Ryan Brown
General Counsel
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
GLPG
Galapagos NV
78.69-0.46-0.58%
DNLI
Denali Therapeutics Inc
53.28-0.73-1.35%
HALO
Halozyme Therapeutics Inc
47.35+0.94+2.03%
ACAD
ACADIA Pharmaceuticals Inc
20.73-0.42-1.99%
NVTA
Invitae Corp
35.23-2.41-6.40%